Review
Oncology
Thierry Roumeguere, Fouad Aoun, Simone Albisinni, Georges Mjaess
Summary: Targeting Prostate-Specific Membrane Antigen (PSMA) with antibodies has shown great promise in personalized medicine for prostate cancer patients, both for diagnostic and therapeutic purposes. Recent developments in PSMA-targeting antibodies have led to groundbreaking advances in PCa diagnosis and treatment, with the use of different radionuclides and drug conjugates showing potential in clinical trials. Despite safety concerns in some trials, PSMA has been validated as a crucial immunoconjugate target for further clinical investigation.
CURRENT OPINION IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Liujuan Zhou, Fan Yang, Zhaoshuai Bai, Xiaohui Zhou, Zhihai Zhang, Zhihang Li, Junyuan Gong, Junqi Yu, Liqiang Pan, Chan Cao, James J. Chou
Summary: One challenge in improving clinical outcomes of antibody drug conjugates (ADCs) is overcoming cancer resistance to the antibody and/or drug components of ADCs. In this study, a self-assembled left-handed DNA (L-DNA) oligonucleotide was used to link combinatory single-domain antibodies and toxin payloads for tunable and adaptive delivery of ADCs. The newly constructed ADCs with L-DNA scaffold showed promising properties in vitro and in vivo. This suggests that the L-DNA based modular ADC (MADC) platform is a viable option for generating therapeutic ADCs and expanding the therapeutic window.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Review
Engineering, Multidisciplinary
Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen
Summary: The modification of therapeutic antibodies is booming in research and development to improve efficacy. China, as an active player in the biopharmaceutical field, shows a great demand and potential in this area.
Article
Oncology
Jamie M. Sperger, Kyle T. Helzer, Charlotte N. Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R. Kaufmann, David J. Niles, Erika Heninger, Nicholas R. Rydzewski, Liguo Wang, Liewei Wang, Rendong Yang, Yanan Ren, Jonathan W. Engle, Peng Huang, Christos E. Kyriakopoulos, Susan F. Slovin, Howard R. Soule, Shuang G. Zhao, Manish Kohli, Scott T. Tagawa, Weibo Cai, Scott M. Dehm, Joshua M. Lang
Summary: This study analyzed the expression of biomarkers in prostate cancer patients and demonstrated that TROP-2 can serve as a cell surface target for isolating circulating tumor cells, and it may serve as a predictive biomarker for antibody-drug conjugates.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Aleksei E. E. Machulkin, Ekaterina A. A. Nimenko, Nikolay U. U. Zyk, Anastasiia A. A. Uspenskaia, Galina B. B. Smirnova, Irina I. I. Khan, Vadim S. S. Pokrovsky, Alexander N. N. Vaneev, Roman V. V. Timoshenko, Vugara V. V. Mamed-Nabizade, Maria V. V. Zavertkina, Alexander Erofeev, Petr Gorelkin, Alexander G. G. Majouga, Nikolay V. V. Zyk, Elena S. S. Khazanova, Elena K. K. Beloglazkina
Summary: In this study, a novel small-molecule PSMA-targeted conjugate PSMA-Abi was synthesized, which showed a preferential effect on prostate tumor cells with minimal side effects.
Article
Biochemical Research Methods
Brian Agnew, Shanhua Lin, Terry Zhang, Robert Aggeler, Trina Mouchahoir, John Schiel
Summary: ADCs are a rapidly growing modality for cancer treatment, which increases the complexity of analytical method development. This study utilized a specific conjugation strategy to prepare ADC mimetics, which were exhaustively characterized using high-resolution mass spectrometry-based approaches, demonstrating their utility and effectiveness in deep characterization.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
(2021)
Article
Chemistry, Analytical
Yanbo Wang, Mingyang Wang, Haipeng Yu, Ge Wang, Pengxin Ma, Shuang Pang, Yiming Jiao, Aihua Liu
Summary: PSA is an important index for prostate cancer diagnosis and treatment. In this study, a biopanning method for PSA was established using a pIII phage display library. Two phage monoclonal antibodies specific to PSA were obtained, and an ELISA system was constructed for detecting tPSA with high accuracy.
SENSORS AND ACTUATORS B-CHEMICAL
(2022)
Article
Oncology
Guang Wu, Lan Li, Mengnan Liu, Chunyan Chen, Guangze Wang, Zewei Jiang, Yaqian Qin, Licai He, Hongzhi Li, Jiawei Cao, Haihua Gu
Summary: The generated HzMUC1-ADC demonstrated promising targeted therapy potential for pancreatic cancer, as it inhibited tumor cell growth, induced apoptosis, and significantly reduced xenograft tumor growth in vivo.
CANCER CELL INTERNATIONAL
(2022)
Article
Pharmacology & Pharmacy
Arnold Lee
Summary: Loncastuximab tesirine is an antibody-drug conjugate developed for the treatment of B cell lymphomas, currently approved in the US for specific types of lymphoma treatment while being researched for treatments of other types of lymphoma.
Article
Oncology
Yi Zhang, Silvia K. Tacheva-Grigorova, Janette Sutton, Zea Melton, Yvonne S. L. Mak, Cecilia Lay, Bryan A. Smith, Tao Sai, Thomas Van Blarcom, Barbra J. Sasu, Siler H. Panowski
Summary: The purpose of this study was to explore the role of DLL3 in SCLC and evaluate the safety and efficacy of DLL3 CAR T cells. The results showed that DLL3 CAR T cells had a strong anti-tumor effect and no significant tissue damage was observed in the brain and pituitary. Therefore, this study provides a basis for further evaluation of the potential role of DLL3 CAR T cells in the treatment of SCLC.
CLINICAL CANCER RESEARCH
(2023)
Article
Hematology
Jithma P. Abeykoon, Julia Vaxman, Sanjay V. Patel, Shaji Kumar, Gabriella C. Malave, Kimberly S. Young, Sikander Ailawadhi, Jeremy T. Larsen, Angela Dispenzieri, Eli Muchtar, Wilson I. Gonsalves, Taxiarchis Kourelis, Nelson Leung, Rahma Warsame, Ronald S. Go, Leif Bergsagel, Martha Q. Lacy, S. Vincent Rajkumar, Morie A. Gertz, Prashant Kapoor
Summary: A study found that 75% of patients treated with Belantamab mafodotin (BLMF) for advanced multiple myeloma experienced ocular toxicity, with 69% developing keratopathy. Among patients who had to permanently discontinue or reduce BLMF treatment due to ocular toxicity, 70% experienced progression of multiple myeloma within 3 months.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Shaojie Liu, Donghui Han, Chao Xu, Fa Yang, Yu Li, Keying Zhang, Xiaolong Zhao, Jiayu Zhang, Tong Lu, Shiqi Lu, Changhong Shi, Rui Zhang, An-Gang Yang, Aizhi Zhao, Weijun Qin, Bo Yang, Weihong Wen
Summary: This study successfully developed an antibody-drug conjugate (ADC) targeting CD248, which showed effective killing of activated HSCs in vitro and excellent anti-fibrotic effects in a mouse model of liver fibrosis. The study also evaluated the biosafety and reproductive safety of the ADC in vivo.
MOLECULAR MEDICINE
(2022)
Article
Nanoscience & Nanotechnology
Bing Xu, Mengmeng Yan, Fei Zhou, Desheng Cai, Wenbo Guo, Xiaohui Jia, Runping Liu, Tao Ma, Tong Li, Feng Gao, Penglong Wang, Haimin Lei
Summary: The study developed self-assembled nanoparticles that respond to PSMA and esterase, leading to efficient delivery of CPT for cancer therapy. These nanoparticles exhibited programmable release of CPT at the tumor site, providing excellent cytotoxic selectivity and antitumor activity against PSMA-expressing cells, demonstrating a promising strategy for efficient drug delivery.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Oncology
Diana Canals Hernaez, Michael R. Hughes, Yicong Li, Ilaria Mainero Rocca, Pamela Dean, Julyanne Brassard, Erin M. Bell, Ismael Samudio, Anne-Marie Mes-Masson, Yoshiki Narimatsu, Henrik Clausen, Ola Blixt, Calvin D. Roskelley, Kelly M. McNagny
Summary: Podocalyxin is a key cell surface sialomucin that plays a role in tumor metastasis and poor prognosis, with a novel antibody PODO447 showing specificity in targeting tumor cells. PODO447 functions effectively in killing various tumor cell lines and targeting human tumors in xenograft models.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Julyanne Brassard, Michael R. Hughes, Calvin D. Roskelley, Kelly M. McNagny
Summary: Finding the ideal epitope for ADC development is crucial. Mucins are ideal carriers of altered glycoepitopes and three types of glycoepitopes are described. Clinical and pre-clinical results of ADCs targeting MUC1 or podocalyxin glycoepitopes are reviewed, and methods to improve glycoepitope-targeting ADCs are discussed.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2022)
Meeting Abstract
Oncology
Zachery R. Reichert, Michael Edward Devitt, Joshi J. Alumkal, David C. Smith, Megan Veresh Caram, Philip Palmbos, Ulka N. Vaishampayan, Ajjai Shivaram Alva, Thomas Braun, Sarah Elizabeth Yentz, Phoebe A. Tsao, Robert Dreicer, Frank Cameron Cackowski, Neel Shah, Emma Dean, Simon Smith, Elisabeth I. Heath
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Irene Tsung, Edward Green, Phillip Lee Palmbos, Zachery R. Reichert, Ulka N. Vaishampayan, David C. Smith, Megan Veresh Caram, Sarah Elizabeth Yentz, Stephanie Daignault-Newton, Zachery Sloan, Laura Hurley, Ajjai Shivaram Alva
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Panagiotis J. Vlachostergios, Muhammad J. Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne, Daniel J. A. Margolis, Francesca Khani, Neil H. Bander, Douglas S. Scherr, Scott T. Tagawa
Summary: PSMA-PET imaging shows higher detection rate and accuracy compared to mpMRI in localized prostate cancer, with potential implications for management and treatment strategies.
Correction
Oncology
Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, Daniel J. George
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Zeina Nahleh, Gary H. Lyman, Richard L. Schilsky, Douglas E. Peterson, Scott T. Tagawa, Mariana Chavez-MacGregor, Bryan Rumble, Shilpi Gupta
Summary: This report provides an update on currently approved oncology biosimilars and identifies knowledge gaps in the management of cancer patients. Despite years of clinical experience, there are variations in the use of oncology biosimilars. ASCO supports considering biosimilars and reference products equally effective and suggests their use as cost-effective alternatives in cancer care.
JCO ONCOLOGY PRACTICE
(2022)
Article
Hematology
Babak B. Navi, Cenai Zhang, Carla P. Sherman, Richard Genova, Natalie M. LeMoss, Hooman Kamel, Scott T. Tagawa, Ashish Saxena, Allyson J. Ocean, Scott E. Kasner, Mary Cushman, Mitchell S. Elkind, Ellinor Peerschke, Lisa M. DeAngelis
Summary: Hematologic and embolic biomarkers soon after AIS in cancer patients may be associated with subsequent adverse clinical outcomes, particularly recurrent thromboembolism or death.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Urology & Nephrology
Steven B. Goldenthal, Melissa A. Reimers, Udit Singhal, Mark Farha, Rohit Mehra, Morand Piert, Jeffrey J. Tosoian, Parth K. Modi, Nicole Curci, James Peabody, Eduardo Kleer, David C. Smith, Todd M. Morgan
Summary: This study reports five cases of peritoneal carcinomatosis following robotic-assisted radical prostatectomy (RARP), which occurred relatively late and may be related to the preoperative pathological stage. The use of next-generation imaging modalities, such as PSMA PET, can help identify metastases. Further research and classification are needed to improve the understanding and management of this atypical presentation.
Correction
Oncology
Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, Daniel J. George
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Review
Biotechnology & Applied Microbiology
Mariane S. Fontes, Daniel Vargas Pivato de Almeida, Clarissa Cavalin, Scott T. Tagawa
Summary: Urothelial carcinoma is a common genitourinary malignancy with poor prognosis. Sacituzumab govitecan, an ADC targeting Trop-2, has shown promising efficacy and safety in the treatment of locally advanced and metastatic urothelial cancer. However, not all patients respond to this therapy, highlighting the importance of understanding resistance mechanisms and predictive biomarkers for improved outcomes.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atkins, John D. Powderly, Philip D. Leming, Evan J. Lipson, Igor Puzanov, David C. Smith, Janis M. Taube, Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Drew M. Pardoll, Jeffrey A. Sosman, F. Stephen Hodi
Summary: PD-1 blockade therapy can effectively reduce tumors and improve survival rates in patients with advanced melanoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
James J. J. Harding, Christiane Jungels, Jean-Pascal Machiels, David C. C. Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K. K. Abou-Alfa
Summary: This study investigated the safety, tolerability, and maximum tolerated dose of INCB062079, an oral selective FGFR4 inhibitor, in patients with advanced solid tumors. The results showed that the drug demonstrated a manageable safety profile and inhibited tumor growth at appropriate doses. However, the study was terminated prematurely due to difficulties in patient recruitment.
Article
Oncology
Allison J. Schepers, David C. Smith, Rachel L. McDevitt
Summary: This study describes the development and implementation of a protocol for complete outpatient administration of TIP chemotherapy. Evaluation of patients receiving outpatient TIP treatment showed that 77% of chemotherapy cycles were administered in the outpatient setting, resulting in a savings of 50 inpatient bed days in one year. No patients experienced dose reduction or delay in chemotherapy or acute toxicities during outpatient TIP treatment.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Oncology
Joseph Thomas, Michael Sun, Ted Getz, Benedict Ho, Jones T. Nauseef, Scott T. Tagawa
Summary: The standard treatment for advanced urothelial carcinoma includes platinum chemotherapy and immunotherapy. Antibody-drug conjugates (ADCs) have emerged as a new therapeutic option for patients with advanced urothelial carcinoma, offering improved efficacy and reduced systemic toxicity. Several ADCs have received approval and demonstrated effectiveness in clinical studies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Andrew L. Coveler, David C. Smith, Tycel Phillips, Brendan D. Curti, Sanjay Goel, Amitkumar N. Mehta, Timothy M. Kuzel, Svetomir N. Markovic, Olivier Rixe, David L. Bajor, Thomas F. Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K. Gopal, Paolo Caimi, Elisabeth Heath, John A. Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W. Schmitt, Juneko E. Grilley-Olson
Summary: SEA-CD40, an investigational antibody that activates CD40, demonstrated tolerability and potent immune activation in patients with solid tumors and lymphoma, showing evidence of antitumor activity. Further evaluation of SEA-CD40 as a component of combination therapy is warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Cardiac & Cardiovascular Systems
Babak B. Navi, Cenai Zhang, Jed H. Kaiser, Vanessa Liao, Mary Cushman, Scott E. Kasner, Mitchell S. Elkind, Scott T. Tagawa, Saketh R. Guntupalli, Mario F. L. Gaudino, Agnes Y. Y. Lee, Alok A. Khorana, Hooman Kamel
Summary: Cancer is an independent risk factor for perioperative arterial ischemic events.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2023)